Source:http://linkedlifedata.com/resource/pubmed/id/15751639
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2005-3-8
|
pubmed:abstractText |
Pharmacokinetic modulating chemotherapy (PMC) is a new therapeutic regimen for advanced colorectal carcinoma, in which high serum 5-FU concentrations are attained through the inhibition of 5-FU degradation by simultaneously administered uracil. A 67-year-old woman, presented with unresectable multiple hepatic and pulmonary metastases following abdominoperineal resection of rectal carcinoma, was successfully treated by the PMC. The patient was initially treated by 600 mg/m2/day of 5-FU infusion, once a week, and subsequently 5-FU doses were increased to 750 mg/m2/day and then to 1,200 mg/m2/day. Hepatic metastases responded at the dose of 750 mg/m2/day and pulmonary metastases responded at the dose of 1,200 mg/m2/day. The patient remains partial response (>21 months). 5-FU serum concentrations were higher at night time and the peak concentration of 5-FU was obtained at 3 a.m. 5-FU Cmax of 600 mg/m2/day, 750 mg/m2/day and 1,200 mg/m2/day were 254, 329, 531 ng/ml, respectively. The experience of this case, together with literature review, suggests that pulmonary metastases are more resistant to 5-FU than hepatic metastases in patients with colorectal carcinoma. The high serum 5-FU concentrations at night suggest the chronomodulating nature of PMC and are effective for metastatic colorectal carcinoma.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Tegafur,
http://linkedlifedata.com/resource/pubmed/chemical/UFT(R) drug,
http://linkedlifedata.com/resource/pubmed/chemical/Uracil
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0385-0684
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
32
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
231-3
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15751639-Adenocarcinoma,
pubmed-meshheading:15751639-Aged,
pubmed-meshheading:15751639-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15751639-Combined Modality Therapy,
pubmed-meshheading:15751639-Drug Administration Schedule,
pubmed-meshheading:15751639-Drug Combinations,
pubmed-meshheading:15751639-Female,
pubmed-meshheading:15751639-Fluorouracil,
pubmed-meshheading:15751639-Humans,
pubmed-meshheading:15751639-Liver Neoplasms,
pubmed-meshheading:15751639-Lung Neoplasms,
pubmed-meshheading:15751639-Rectal Neoplasms,
pubmed-meshheading:15751639-Tegafur,
pubmed-meshheading:15751639-Uracil
|
pubmed:year |
2005
|
pubmed:articleTitle |
[Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report].
|
pubmed:affiliation |
Dept of Surgery, Niitsu Medical Center Hospital.
|
pubmed:publicationType |
Journal Article,
English Abstract,
Case Reports
|